Oncolytics begins patient enrollment in U.S. phase 1/ 2 malignant gliomas trial

By E. Janene Geiss

Philadelphia, July 11 - Oncolytics Biotech Inc. said Tuesday that it has begun patient enrollment in its clinical trial to investigate the use of Reolysin for patients with recurrent malignant gliomas.

The trial is an open-label dose escalation phase 1/ 2 trial in which a single dose of Reolysin is administered by infusion to patients with recurrent malignant gliomas that are refractory to standard therapy, according to a company news release.

The administration involves the stereotactically guided placement of a needle into the tumor through which Reolysin will be administered or infused into the tumor mass and surrounding tissue using a pump.

The primary objective of the study is to determine the maximum tolerated dose, dose-limiting toxicity and safety profile of Reolysin.

Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumor activity, officials said.

Oncolytics is a Calgary, Alta., biotechnology company focused on cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.